Our findings reveal a conserved molecular signature linking SCI and depression, highlighting crucial neuroinflammatory pathways, especially the IκB/NF-κB signaling pathway, and identifying Nfkbia as a promising therapeutic target. This evidence concerns the gene NFKB1 and depressive symptom measurement.